Competing interests
ONCOLOGY, MAY
Dr. Michael Cecchini reports consulting fees from Eisai Inc., Agios Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Macrogenics, Seattle Genetics, DAVA Oncology, Bayer Pharmaceuticals, Regeneron, and Parthenon Therapeutics. Dr. JMC receives research funding to his institution from Merus, Roche, Servier, and Bristol-Myers Squibb. He receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences, and Apexigen; he has also received honoraria for being on the advisory boards of Incyte and Blueprint Medicines. Dr. EMS reports consulting fees from Ideaya Biosciences and DSMB for Novartis and research support to institution from GSK. May Cho reports honoraria from presentations and advisory boards and travel support from AstraZeneca. EK reports advisory board support from Eli Lilly and Relay Therapeutics, honoraria from presentations from Eisai Inc and Seattle Genetics, consulting fees from Eisai Inc, Taiho, Eli Lilly, and Relay Therapeutics as well as stock from ROMTech. EK also reports institutional grants or contracts from NGM Biopharmaceuticals, Erytech, Fibrogen, Eureka, Merck, Bristol-Myers Squibb, Astellas, Boston Biomedical, AstraZeneca, Celgene, Halozyme, Sanumed, Epicentryx, and Medimmune. LG reports consulting or advisory roles from QED Therapeutics, Genentech, Merck, AstraZeneca, Exelixis, Boehringer Ingelheim, Cardinal Health, Athenum Consulting and Relay Therapeutics. LG also reports research funding from Bristol-Myers Squibb, Agios, ASLAN Pharmaceuticals, Beigene, Basilea, and Merck. JC reports grants or contracts to institution from Merck and Brooklyn Immunotherapeutics, and consulting fees to himself from Eli Lilly, Merck, AstraZeneca, Foundation Medicine, Daiichi Sankyo, Amgen, Bristol-Myers Squibb, Astellas, Turning Point Therapeutics, Silverback Therapeutics, Novartis, Coherus Biosciences, Geneos, Roche, and Guardant Health. JC also reports payments or honoraria for presentations from Merck and Bristol-Myers Squibb, Data Safety Monitoring Board participation from Yiviva and Daiichi Sankyo, and stock or stock options from Amgen as well as current employment by Amgen.